Suresh Chandrasekaran, MD
Interventional Cardiology · Midwest City, OKNPI 1649376427
Payments from drug & device makers
Across 764 payments — averaging $395.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$122K
- AstraZeneca$61K
- Boehringer Ingelheim$36K
- Johnson & Johnson$28K
- Esperion Therapeutics, Inc.$18K
- Lilly USA, LLC$15K
- plus $21K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 80 | $122,078 |
| AstraZeneca | 134 | $60,538 |
| Boehringer Ingelheim | 88 | $36,285 |
| Johnson & Johnson | 111 | $28,371 |
| Esperion Therapeutics, Inc. | 27 | $18,457 |
| Lilly USA, LLC | 39 | $14,558 |
| E.r. Squibb & Sons, L.L.C. | 60 | $12,239 |
| Merck | 48 | $3,543 |
| Medtronic(2 entities) | 8 | $1,156 |
| Amgen | 30 | $1,034 |
| Novartis | 44 | $591 |
| Globus Medical | 3 | $563 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $507 |
| Atricure, Inc. | 4 | $315 |
| Shockwave Medical, Inc | 2 | $214 |
| Sanofi-aventis U.S. LLC | 6 | $202 |
| Vifor Pharma, Inc. | 10 | $197 |
| Abbott | 7 | $169 |
| Amarin Pharma, Inc. | 10 | $164 |
| Abiomed | 1 | $131 |
| Pfizer | 8 | $125 |
| Kestra Medical Technology Services, Inc. | 2 | $59 |
| Regeneron Healthcare Solutions, Inc. | 4 | $56 |
| Lexicon Pharmaceuticals, Inc. | 2 | $51 |
| Lundbeck LLC | 2 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $14 |
| Gilead | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $13 |
How this compares
$301,780 in reported general payments places this provider in the 90th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Midwest City
- Jerome MathiasMidwest City$11K
- Mohammed AhmedMidwest City$9K
- Naeem TahirkheliOklahoma City$8.6M
- Kamran MuhammadTulsa$5.7M
- Mohammad GhaniOklahoma City$1.8M
- George ChrysantOklahoma City$873K
- Usman BaberOklahoma City$736K
- Jeffrey SparlingOklahoma City$381K
- Wayne LeimbachTulsa$283K
- Thomas McGarryOklahoma City$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.